Glioblastoma Clinical Trials

170 recruiting

Glioblastoma Trials at a Glance

294 actively recruiting trials for glioblastoma are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 2 with 109 trials, with the heaviest enrollment activity in New York, Boston, and Houston. Lead sponsors running glioblastoma studies include M.D. Anderson Cancer Center, Mayo Clinic, and Northwell Health.

Browse glioblastoma trials by phase

Treatments under study

About Glioblastoma Clinical Trials

Looking for clinical trials for Glioblastoma? There are currently 170 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glioblastoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glioblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 294 trials

Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med LLC48 enrolled4 locationsNCT05283330
Recruiting
Phase 1

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern University30 enrolled1 locationNCT06410248
Recruiting
Phase 2

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
BioNTech SE75 enrolled6 locationsNCT07297212
Recruiting
Phase 1

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Glioblastoma MultiformeRecurrent Glioblastoma
Boston Scientific Corporation36 enrolled9 locationsNCT05303467
Recruiting
Phase 3

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

Glioblastoma
GT Medical Technologies, Inc.766 enrolled4 locationsNCT07195591
Recruiting
Phase 3

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Glioblastoma
NovoCure GmbH741 enrolled93 locationsNCT06556563
Recruiting
Phase 1

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

GlioblastomaGliomaGlioblastoma Multiforme of Brain
Tetragon Biosciences Ltd30 enrolled3 locationsNCT07464925
Recruiting
Phase 1

Sonodynamic Therapy in Patients With Recurrent GBM

GBMGlioblastoma MultiformeRecurrent Glioblastoma
Shayan Moosa, MD11 enrolled1 locationNCT06039709
Recruiting
Phase 1Phase 2

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA116 enrolled17 locationsNCT05765812
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled4 locationsNCT07326566
Recruiting
Phase 1

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

GlioblastomaAstrocytomaProgressive Disease
Masonic Cancer Center, University of Minnesota9 enrolled1 locationNCT07560865
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 3

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

GlioblastomaGBMRecurrent Glioblastoma
CarThera560 enrolled48 locationsNCT05902169
Recruiting
Phase 1

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

High Grade GliomaAdult GlioblastomaWHO Grade III or IV Malignant Glioma
University of Florida28 enrolled1 locationNCT04573140
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 2

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Glioblastoma (GBM)
Diakonos Oncology Corporation180 enrolled16 locationsNCT06805305
Recruiting
Phase 2Phase 3

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma
Global Coalition for Adaptive Research2,250 enrolled63 locationsNCT03970447
Recruiting

Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors

Breast CancerPancreatic CancerSarcoma+3 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology26 enrolled1 locationNCT07552467
Recruiting
Not Applicable

NK Cell Therapy for Malignant Solid Brain Tumors

Brain MetastasisGlioblastoma Multiforme (GBM)Glioblastoma (GBM)+2 more
Peking University Third Hospital27 enrolled4 locationsNCT07552233
Recruiting
Phase 1

Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

Glioblastoma
Johann Wolfgang Goethe University Hospital42 enrolled5 locationsNCT03383978